Daiichi Sankyo Company, Limited

$16.16+1.00%(+$0.16)
TickerSpark Score
65/100
Solid
80
Valuation
90
Profitability
45
Growth
80
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DSKYF research report →

52-Week Range7% of range
Low $15.16
Current $16.16
High $29.15

Companywww.daiichisankyo.com

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic.

CEO
Hiroyuki Okuzawa
IPO
2008
Employees
18,726
HQ
Tokyo, JP

Price Chart

-38.58% · this period
$28.90$22.32$15.75May 20Nov 18May 20

Valuation

Market Cap
$29.41B
P/E
18.81
P/S
2.28
P/B
2.94
EV/EBITDA
14.72
Div Yield
2.93%

Profitability

Gross Margin
68.49%
Op Margin
9.80%
Net Margin
12.24%
ROE
15.74%
ROIC
6.58%

Growth & Income

Revenue
$2.14T · 13.26%
Net Income
$261.51B · -11.58%
EPS
$140.61 · -9.84%
Op Income
$208.62B
FCF YoY
61.93%

Performance & Tape

52W High
$29.15
52W Low
$15.16
50D MA
$17.51
200D MA
$21.29
Beta
-0.17
Avg Volume
13.24K

Get TickerSpark's AI analysis on DSKYF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Our DSKYF Coverage

We haven't published any research on DSKYF yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate DSKYF Report →

Similar Companies